Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

4-(Dimeth-oxy-meth-yl)phenyl 2,3,4,6-tetra-O-acetyl-?-d-glucopyran-oside.

ABSTRACT: The enanti-omerically pure title compound, C(23)H(30)O(12), crystallizes in the chiral space group P2(1)2(1)2(1). The O-acetyl-ated-glucopyran-oside moiety adopts a chair conformation. Numerous C-H?O inter-actions as well as a C-H?? inter-action are present in the crystal structure.

SUBMITTER: Zipp CF

PROVIDER: S-EPMC3344139 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

4-(Dimeth-oxy-meth-yl)phenyl 2,3,4,6-tetra-O-acetyl-β-d-glucopyran-oside.

Zipp Caitlin F CF Fernandes Manuel M Marques Helder M HM Michael Joseph P JP

Acta crystallographica. Section E, Structure reports online 20120328 Pt 4

The enanti-omerically pure title compound, C(23)H(30)O(12), crystallizes in the chiral space group P2(1)2(1)2(1). The O-acetyl-ated-glucopyran-oside moiety adopts a chair conformation. Numerous C-H⋯O inter-actions as well as a C-H⋯π inter-action are present in the crystal structure. ...[more]

PMID: 22606142

Similar Datasets

3,4-Dicyano-phenyl 2,3,4,6-tetra-O-acetyl-?-d-glucopyran-oside.

Project description:The title compound, C(22)H(22)N(2)O(10), was prepared by the glycosidation method through nitrite displacement on substituted nitro-phthalonitrile. The mol-ecule contains a benzene ring, two nitrile groups and an acetyl-protected d-glucose fragment which adopts a chair conformation. The absolute configuration was determined by the use of d-glucose as starting material. All substituents of the protected sugar are in equatorial positions, with the exclusive presence of the ?-anomer. The crystal packing is stabilized by C-H?O and C-H?N hydrogen-bonding inter-actions.

| S-EPMC2915021 | biostudies-literature

4-Formyl-phenyl 2,3,4,6-tetra-O-acetyl-?-d-glucopyran-oside.

Project description:The pyran-oside ring in the title compound, C(21)H(24)O(11), has a chair conformation with the substituted benzene ring occupying an equatorial position. The crystal packing is dominated by C-H?O inter-actions that lead to the formation of supra-molecular layers in the ab plane.

| S-EPMC3099765 | biostudies-literature

n-Propyl 2,3,4,6-tetra-O-acetyl-?-d-glucopyran-oside.

Project description:THE TITLE COMPOUND [SYSTEMATIC NAME: (2R,3R,4S,5R,6R)-2-(acet-oxy-meth-yl)-6-propoxytetra-hydro-2H-pyran-3,4,5-triyl triacetate], C(17)H(26)O(10), was formed by a Koenigs-Knorr reaction of 2,3,4,6-tetra-O-acetyl-?-d-glucopyranosyl bromide and n-propanol. The central ring adopts a chair conformation. The crystal does not contain any significant inter-actions such as hydrogen bonds.

| S-EPMC3569225 | biostudies-literature

2,3,4,6-Tetra-O-acetyl-2-phthalimido-?-d-glucopyran-oside.

Project description:In the crystal structure of the title compound, C(24)H(27)NO(11), a substituted tetra-acetyl glucopyran-oside derivative, weak inter-molecular C-H?O hydrogen bonds link the mol-ecules into ribbons propagated in [010]. The d configuration has been attributed on the basis of the synthesis and the ? anomer has been determined from the structure.

| S-EPMC3011788 | biostudies-literature

Isopropyl 2,3,4,6-tetra-O-acetyl-?-d-glucopyran-oside.

Project description:The title compound, C(17)H(26)O(10), was formed by a Koenigs-Knorr reaction of 2,3,4,6-tetra-O-acetyl-?-d-glucopyranosyl bromide and propan-2-ol. The central ring adopts a chair conformation. The crystal does not contain any significant inter-molecular inter-actions.

| S-EPMC3569224 | biostudies-other

2,2,5,7,8-Penta-methyl-chroman-6-yl 2,3,4,6-tetra-O-acetyl-α-d-glucopyran-oside from synchrotron data.

Project description:The crystal structure of the title compound, C(28)H(38)O(11), solved and refined against synchrotron diffraction data, contains two formula units in the asymmetric unit. In both mol-ecules, the dihydro-pyran ring along with its methyl substituents is disordered and adopts two alternative half-chair conformations. The occupancy of the major conformers of the two mol-ecules refined to 0.858 (5) and 0.523 (5).

| S-EPMC3052099 | biostudies-literature

4-Formyl-phenyl 2,3,4,6-tetra-O-acetyl-β-d-galactopyran-oside.

Project description:The galactose ring in the title compound, C(21)H(24)O(11), has a chair conformation with the substituted benzene ring occupying an equatorial position. The crystal packing features C-H⋯O inter-actions that lead to the formation of supra-molecular layers in the ab plane.

| S-EPMC3099913 | biostudies-literature

4-Formyl-phenyl 2,3,4,6-tetra-O-acetyl-β-d-allopyran-oside.

Project description:The title compound, C(21)H(24)O(11), crystallizes exclusively as the β-anomer. The substituent of the protected sugar at position C-3 is in the axial position, while all other groups are in equatorial positions. The pyran-oside ring adopts a stable chair conformation.

| S-EPMC2969774 | biostudies-literature

4-Methoxy-phenyl 2,3,4,6-tetra-O-acetyl-1-thio-α-d-mannopyran-oside.

Project description:The title compound, C(21)H(26)O(10)S, was synthesized in a single step from mannose penta-acetate. The mol-ecular structure confirms the α configuration of the anomeric thioaryl substituent. Spectroscopic and melting-point data obtained for the title compound are in disagreement with those previously reported, indicating the previously reported synthesis [Durette & Shen (1980 ▶). Carbohydr. Res. 81, 261-274] to be erroneous. The crystal structure is stabilized by weak inter-molecular C-H⋯O hydrogen bonds.

| S-EPMC2962034 | biostudies-literature

6,12,18,24-Tetra-meth-oxy-4,10,16,22-tetra-kis-[(meth-oxy-carbon-yl)meth-oxy]-2,8,14,20-tetra-kis-(2-phenyl-eth-yl)resorcin[4]arene.

Project description:The title compound, C(76)H(80)O(16), is a macrocyclic structure. This novel resorcin[4]arene derivative has (meth-oxy-carbon-yl)meth-oxy 'head' groups on the upper rim. The compound has a C(2v) 'boat' geometry and there are a range of C-H?O contacts in the crystal structure.

| S-EPMC3254447 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data